From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Sun, 9 Feb 2020 18:23:24 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: Investigational compound remdesivir, developed by UAB and NIH

researchers, being used for treatment of novel coronavirus

WOW! Idid not know that. Good talking point for press conferences.

From: Folkers, Greg (NIH/NIAID) [E] CO)

Sent: Sunday, February 9, 2020 1:13 PM
Subject: Investigational compound remdesivir, developed by UAB and NIH researchers, being used for
treatment of novel coronavirus

Investigational compound remdesivir, developed by UAB and
NIH researchers, being used for treatment of novel

coronavirus
by Savannah Koplon

e February 07, 2020
e@ Print

 

. Richard Whitley, M.D., Distinguished Professor at UAB and principal investigator
of the U19 grant
The investigational drug remdesivir, developed through research conducted through the Antiviral Drug
Discovery and Development Center, or AD3C, and centered at the University of Alabama at Birmingham,
is being used to treat select infected patients in the United States and in China who have been affected
by the outbreak of novel coronavirus (2019-nCoV).

UAB was awarded a $37.5 million, five-year U19 grant from the National Institute of Allergy and
Infectious Diseases Centers of Excellence for Translational Research to study and develop treatment for
high-priority emerging infections. Work has been taking place in earnest to develop drugs for emerging
influenza, flaviviruses (dengue, West Nile virus and Zika), coronaviruses that cause SARS and MERS, and
alphaviruses such as Venezuelan equine encephalitis virus and chikungunya. The grant is a multi-

NIH-002021
